Reddi Honey V, McIver Bryan, Grebe Stefan K G, Eberhardt Norman L
Department of Medicine/Division of Endocrinology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA.
Endocrinology. 2007 Mar;148(3):932-5. doi: 10.1210/en.2006-0926. Epub 2006 Aug 31.
The American Cancer Society estimates 30,180 new cases of thyroid cancer in the United States in 2006. Of all thyroid cancers, 15-20% are follicular thyroid carcinoma (FTC), making this the second most common thyroid malignancy (after papillary carcinoma). A proportion of FTC has been found to be associated with a chromosomal translocation, t (2, 3)(q13;p25), which fuses the thyroid-specific transcription factor paired box-8 with the peroxisome proliferator-activated receptor-gamma nuclear receptor, a ubiquitously expressed transcription factor. This fusion event causes expression of a paired box-8/peroxisome proliferator-activated receptor-gamma fusion protein (PPFP). PPFP is detected in approximately 30% of FTC. In this report we review data on the role of PPFP in FTC, its mechanism of oncogenesis, and PPFP targeting as a strategy in thyroid cancer treatment.
美国癌症协会估计，2006年美国有30180例甲状腺癌新发病例。在所有甲状腺癌中，15%至20%为滤泡状甲状腺癌（FTC），使其成为第二常见的甲状腺恶性肿瘤（仅次于乳头状癌）。已发现一部分FTC与一种染色体易位t(2,3)(q13;p25)有关，该易位将甲状腺特异性转录因子配对盒8与过氧化物酶体增殖物激活受体γ核受体融合，后者是一种广泛表达的转录因子。这种融合事件导致配对盒8/过氧化物酶体增殖物激活受体γ融合蛋白（PPFP）的表达。在大约30%的FTC中可检测到PPFP。在本报告中，我们综述了关于PPFP在FTC中的作用、其肿瘤发生机制以及将靶向PPFP作为甲状腺癌治疗策略的数据。
